Increased lipoprotein(a) is associated with reduced myocardial vasoreactivity in young healthy men

Atherosclerosis. 2005 Mar;179(1):185-91. doi: 10.1016/j.atherosclerosis.2004.10.007. Epub 2004 Dec 8.

Abstract

Objectives and background: We examined the association between lipoprotein(a) and myocardial vasoreactivity in healthy men.

Methods: Thirty non-smoking healthy men (age 34+/-6 years) were studied: 9 had increased lipoprotein(a) (>200 mg/L) concentrations (lipoprotein(a) 317 (range 218-550) mg/L) and 21 had normal lipoprotein(a) (<200 mg/L) concentrations (lipoprotein(a) 57 (range 13-156) mg/L). The myocardial blood flow measurements were performed basally and during adenosine infusion (140 microg/kg/min) with or without simultaneous physiological hyperinsulinemia (insulin infusion at a rate of 1 mU/kg/min) using positron emission tomography and [(15)O]H(2)O.

Results: Basal myocardial blood flow was similar between the subjects with increased and normal lipoprotein(a) (0.76+/-0.20 and 0.79+/-0.20 mLg(-1) min(-1), NS). Adenosine-stimulated flow tended to be reduced in subjects with increased lipoprotein(a) (3.1+/-0.7 mLg(-1) min(-1) versus 3.7+/-1.1 mLg(-1) min(-1), respectively, p=0.1). During physiological hyperinsulinemia adenosine-stimulated flow was further enhanced in both groups but significantly blunted in subjects with increased lipoprotein(a) (3.7+/-0.8 mLg(-1) min(-1) versus 4.8+/-1.4 mLg(-1) min(-1), respectively, p=0.03). This difference remained significant after simultaneous controlling for BMI, HbA1c, LDL-cholesterol, HDL-cholesterol and blood pressure (p=0.04).

Conclusions: Already young healthy men with lipoprotein(a) concentrations greater than 200mg/L are characterized by impaired myocardial vasoreactivity.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / administration & dosage
  • Adult
  • Blood Pressure
  • Coronary Circulation / drug effects
  • Coronary Circulation / physiology*
  • Heart Rate
  • Humans
  • Lipoprotein(a) / blood*
  • Male
  • Oxygen Radioisotopes
  • Positron-Emission Tomography*
  • Vasodilation / drug effects
  • Vasodilation / physiology*
  • Vasodilator Agents / administration & dosage

Substances

  • Lipoprotein(a)
  • Oxygen Radioisotopes
  • Vasodilator Agents
  • Adenosine